Dear All, First, thank you for being part of a truly wonderful...

Dear All,
First, thank you for being part of a truly wonderful year.
Medlab’s mantra is ‘innovating and redefining medicine’ and as I recap 2016, I feel we have lived up to this.
2016 has witnessed several significant milestones:
• Medlab’s nutraceutical business has grown.
• Our Patent portfolio is strong and maturing
• Nanocelle Atorvastatin study showing stellar results and is moving into bioequivalence work.
• Nanocelle cannabis, probably our most known and accelerated program, is readying for first human trials, currently with HREC.
• TGA has approved Medlab to import Cannabis from Canada.
• Our diabetes/obesity program done in collaboration with The Boden Institute, Sydney University, School of Medicine, has been successful with remarkable results. We are now preparing for phase 2a trials.
• Our depression study, which was done in collaboration with The Princess Alexandra Hospital in Brisbane, has shown very positive results and will now be moving into Phase 2A 1st quarter 2017.
• Medlab’s ASX stock price has shown significant growth the past few months.
As this year draws to a close, we wish to thank everyone involved with Medlab. Your support, commitment and involvement has been most appreciated.
Have a wonderful and safe holiday period. Looking forward to reconnecting in 2017.
Sean Hall
https://www.facebook.com/medlabAUS/


On a different note, our local pharmacy has started to stock Medlab products, and say that they are doing really well, selling quickly after coming in stock. Hopefully they are doing as well at other retailers!